v3.26.1
Stockholders' Equity (Tables)
 3 Months Ended
Mar. 31, 2026
Stockholders' Equity Note [Abstract]  
Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding
The following is a summary of the Company's authorized and issued common and preferred stock as of March 31, 2026 and December 31, 2025:
   Outstanding as of
 AuthorizedIssuedMarch 31, 2026December 31, 2025
Common Stock, par value $0.001 per share
600,000,000 69,773,237 69,773,237 68,996,647 
Series C Preferred Stock, par value $0.001 per share
1,091 1,091 9 9 
Schedule of Stockholders' Equity Note, Warrants or Rights
The following table summarizes the common stock warrants outstanding as of March 31, 2026 and December 31, 2025:
As of March 31, 2026As of December 31, 2025
Issued in Connection With:Exercise PriceExpiration
Date		Number of
Warrants		Common Stock Warrant LiabilityNumber of
Warrants		Common Stock Warrant Liability
December 2024 Offering$3.76 December 16, 202910,000,000 $8,305,196 10,000,000 $8,967,794 
July 2025 Offering - Series A$1.75 (1)— — 13,564,288 3,294,975 
July 2025 Offering - Series B$1.75 July 7, 203014,285,715 16,624,263 14,285,715 16,804,393 
Total24,285,715 $24,929,459 37,850,003 $29,067,162 
(1) The 2025 Series A Warrants were originally scheduled to expire on January 28, 2026, which is 30 days after the date on which the Company first publicly disclosed the U.S. Food and Drug Administration's acceptance of its Biologic License Application for INO-3107. On January 27, 2026, the Company amended each of its 13,564,288 outstanding 2025 Series A Warrants to extend the expiration date from January 28, 2026 to March 31, 2026. All such warrants remained unexercised and expired on March 31, 2026 in accordance with their amended terms.